{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Cardiac"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Fever"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Rash"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Gastrointestinal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55"}]}],"title":"Infections"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"title":"CMV Reactivation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"Febrile Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"Metabolic/laboratory"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Musculoskeletal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Neurologic"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Pulmonary"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Renal/Genitourinary"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Assessed by Common Terminology Criteria for Adverse Events version 3.0. The incidence of all adverse events greater or equal to grade 3 was determined.","groups":[{"description":"Conditioning: Fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1.\n\nCell product: Patients undergo donor peripheral blood stem cell transplant on day 0.\n\nGVHD Prophylaxis: Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is \\>= 1,000/mm\\^3 for three consecutive days.","id":"OG000","title":"Treatment (Nonmyeloablative HCT, TBI)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to day 90","title":"Toxicity of Treatment Regimen Determined by Number of Adverse Events Per Organ System","type":"SECONDARY","unitOfMeasure":"events"}